Replikun Biotech Pty Limited is a private, venture capital backed company established in 2005. Replikun Biotech's origins date back to 1960, when Professor Edwin Westaway isolated the Kunjin virus from Cx. annulirostris mosquitoes in northern Queensland. The virus was given the name of a nearby Aboriginal clan living on the Mitchell River. The discovery of Kunjin was exciting because it provided a safe means of studying flavivirus replication in the laboratory. In 1995, Professor Westaway and Associate Professor Alex Khromykh showed that the structural protein genes could be removed from the Kunjin genome without disturbing replication. The Kunjin genome was an ideal starting point for the development of a safe gene vector that could deliver therapeutic proteins to cells, without ever producing new virus particles in vivo. The result of their work was the invention of the Kunjin replicon. Replikun's founders recognized the significance of using viral-based technology to develop innovative products such as gene therapies and vaccines. The company recognized that at that time, the available technologies had failed to deliver products to market for lack of safety and efficacy. Too many vectors were based on human pathogens with ineradicable pathogenic features. Alternatively, the inefficiency of using naked DNA or RNA molecules to treat subjects precluded the development of protective immune responses. This led to the development of the Kunjin replicon system: self-replicating vectors based on a native Australian flavivirus that never produces virus particles in vivo. Over the next few years the Kunjin replicon technology was found to have a much broader application than gene therapy and vaccination. The self-replicating vectors also produced extraordinarily high yields of therapeutic protein, when used to transfect industrial cell lines used for protein manufacture. In 2002, Associate Professor Khromykh developed packaging cell line technologies for the manufacture of virus-like-particles (VLPs) based on the Kunjin structural proteins. VLPs are very efficient at infecting cells, and therefore act as the perfect delivery system for self-replicating Kunjin replicon vectors.
Prommune is a limited liability biotechnology company that was established to translate the results of laboratory research at the University of Nebraska Medical Center into products that improve the health of humans and animals. Prommune's product focus is on the development of vaccines to infective pathogens as well as to small molecules not typically recognized by the immune system such as drugs of addiction and chemical toxins. The ability to induce immune responses to this variety of antigens is possible by vaccines that contain a unique and patented technology known as MIRADS, Molecular Immune Response Activator and Delivery System.
VaxDesign is an emerging biotechnology company that combines immunology with engineering to find elegant, practical solutions to complex biological problems. We develop, manufacture, and market in vitro assays of the human immune system that are functionally equivalent to the human immune system, and will predict human responses to pharmaceuticals and vaccines much better than existing approaches. Our assays are high-throughput, cost-effective, quantitative, and predictive of human immunological outcomes.
Immune Control Inc. is an early-stage drug discovery and development company testing novel approaches to immune modulation using small molecule, serotonin antagonists. The Company has licensed, exclusively and worldwide, intellectual property from Drexel University College of Medicine, and proposes to benefit from years of medicinal chemistry applied by large pharmaceutical companies to the roles of serotonin analogues in the central nervous system.
Oxxon TherapeuticsÔ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the company has built an initial pipeline through its patented Hi-8Ô PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease. The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV. In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.
Virax Holdings Limited (Virax) is an Australia-based company engaged in the development of biotechnology within Australia. The Company, through its subsidiaries, is principally engaged in the construction of vectors and biologic components, and the manufacture of biologic drugs for clinical trial purposes; the conduct of pre-clinical trials and the preparation for clinical trials; business development associated with the promotion of Virax’s technologies; business development associated with developing collaborative and partnership relationships, and capital raising to provide the funds to undertake the activities of a drug development company. (Source: ARS)
Prima Biomed Limited (Prima) is an Australian biotechnology company with a portfolio of products focussed in the therapeutic area of cancer. The principal activities of the Company, during the fiscal year ended June 30, 2008, were research and commercialization of licensed medical biotechnology through its subsidiaries. Prima has three programs in place. The lead program is in Phase IIa clinical trial and focuses on the development of an ex vivo immunotherapy for ovarian cancer. The second program is focusing on the identification of an antibody to tumour cell target, cripto-1. This program has been partnered with Medarex Inc. The third is focusing on the development of DCtag for use as an adjuvant in cancer and infectious disease vaccines. DCtag can be coupled to a variety of antigens from viruses, bacteria or parasites to induce protective immune responses (antibody and T cells). Its wholly owned subsidiaries include Cancer Vac Pty Ltd, Oncomab Pty Ltd and Panvax Pty Ltd.
Xcyte Therapies, Inc. is a biotechnology company developing a new class of therapeutic products designed to enhance the body's natural immune responses to treat cancer, infectious diseases and other medical conditions associated with weakened immune systems. Xcyte derives its therapeutic products from a patient's own T cells, which are cells of the immune system that orchestrate immune responses and can detect and eliminate cancer cells and infected cells in the body. Xcyte uses its patented and proprietary Xcellerate(TM) Technology to generate activated T cells, called Xcellerated T Cells(TM), from blood that is collected from the patient. Activated T cells are T cells that have been stimulated to carry out immune functions. The Xcellerate(TM) Technology is designed to rapidly activate and expand the number of the patient's T cells outside of the body. Xcyte is currently conducting clinical trials of Xcellerated T Cells(TM) in patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Xcyte(TM), Xcyte Therapies(TM), Xcellerate(TM) and Xcellerated T Cells(TM) are trademarks of Xcyte Therapies, Inc.
Northwest Biotherapeutics, Inc. is a development-stage biotechnology company focused on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to effectively treat cancer. The Company's approach in developing cancer therapies utilizes its capability in the biology of dendritic cells (DC), which are a type of white blood cells that activate the immune system. Northwest Biotherapeutics has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which is called DCVax, and monoclonal antibodies for cancer therapeutics. Its DCVax dendritic cell-based cancer vaccine program is its main technology platform. It combines a dendritic cells with a patient’s own cancer-related biomarkers, or off-the-shelf antigens, to induce immune responses against a patient’s cancer cells. (Source: 10-K)
GammaCan International, Inc. (GammaCan) is a life science company focused on the development of immunotherapy and related approaches to treat cancer. The Company has focused on the use of intravenous immunoglobulins, (IgGs), derived from human plasma to treat melanoma, and other cancers. IgG is derived from human plasma has anti-cancer properties. Its lead product candidate, VitiGam, is a first-in-class, anti-cancer immunotherapy derived entirely from the plasma of donors with vitiligo. It is developing VitiGam to initially address Stage III and Stage IV melanoma and earlier stages of melanoma at a future time. On September 6, 2007, it entered into an agreement for the purchase and sale of blood plasma with DCI Management Group, LLC. (Source: 10KSB)
ViRexx Medical Corp. (ViRexx) is a Canadian-based development-stage biotech company focused on developing therapeutic products that offer better quality of life and a renewed hope for living. Its platform technologies include product candidates for the treatment of hepatitis B, hepatitis C, avian influenza viral infections, biodefense and nanoparticle applications, solid tumors and late-stage ovarian cancer. ViRexx has three platform technologies: Chimigen Vaccines, targeted-autothrombogenic cancer therapy (T-ACT) and antibody-based immunotherapy (AIT). The Chimigen Vaccine Platform is being used to develop immunotherapeutic agents for the treatment of patients with chronic hepatitis B and C virus infections. The Company is developing Occlusin 50 Injection embolization therapy for the treatment of liver cancer and Occlusin 500 AED for the treatment of uterine fibroids. OvaRex MAb, an ovarian cancer treatment, is being considered for front-line therapy in combination with chemotherapy. (Source: 20-F)
http://www.oxfordbiomedica.co.uk
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company's lead product is a gene therapy for Parkinson's disease, which is expected to enter clinical development in 2005, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approx. 65 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co and Biogen Idec.
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is the largest company in the world devoted entirely to human vaccines. Our driving goal is to protect people from infectious diseases by creating safe and effective vaccines. Our company offers the broadest range of vaccines in the world, providing protection against 20 bacterial and viral diseases. We distribute more than 1.6 billion doses of vaccine each year, making it possible to vaccinate more than 500 million people across the globe.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory